Are Lymphoid Aggregates Cancerous or Typically Harmless?

Lymphoid aggregates are clusters of immune cells that turn up in tissue biopsies from nearly every organ system, and the vast majority are completely benign. They represent the immune system doing its job: gathering at a site of inflammation, infection, or chronic irritation and organizing into small nodules that help coordinate a local defense. The challenge is that these harmless clusters can, under a microscope, look uncomfortably similar to low-grade lymphoma, which is why a biopsy report mentioning “lymphoid aggregates” can set off alarm bells for patients and clinicians alike. Understanding where they appear, why they form, and the handful of situations in which they genuinely deserve close monitoring is more useful than a blanket reassurance.

Why Lymphoid Aggregates Form in the First Place

Your immune system does not operate exclusively from lymph nodes and the spleen. When a tissue is chronically exposed to something that provokes an immune response, whether that is a lingering infection, an autoimmune attack, or even normal gut bacteria, immune cells can migrate into that tissue and organize themselves into clusters. These clusters are sometimes called reactive lymphoid aggregates, lymphoid follicles, or, when they become more structurally elaborate, tertiary lymphoid structures. They are essentially pop-up immune outposts.

The molecular machinery behind this process involves signaling molecules that recruit B cells and T cells to a particular spot and keep them there. In the lungs of people with chronic obstructive pulmonary disease (COPD), for example, B cells produce a signaling protein called CXCL13 that attracts more B cells, while another signal called lymphotoxin further amplifies CXCL13 production, creating a self-reinforcing loop that builds and sustains the aggregate.¹ Similar chemistry plays out in the gut, the thyroid, the salivary glands, and virtually any tissue that faces prolonged immune stimulation. The result is the same: a structured knot of immune cells embedded in tissue that did not originally have one.

Bone Marrow Aggregates and the Lymphoma Lookalike Problem

Bone marrow biopsies are one of the most common places pathologists encounter lymphoid aggregates, and they are also where the benign-versus-malignant question causes the most diagnostic anxiety. Benign lymphoid aggregates show up in a minority of bone marrow specimens, yet distinguishing them from non-Hodgkin lymphoma, particularly B-cell lymphomas, can be genuinely difficult.² Both benign and malignant aggregates are clumps of the same cell types, and a quick glance through the microscope does not always settle the matter.

Pathologists rely on a combination of features to make the call. A statistical analysis of distinguishing characteristics found that several features strongly correlate with malignancy: infiltrative (ragged) edges, a predominantly B-cell composition, a location right next to bone trabeculae, a size over 600 micrometers, and abnormal-looking cells.³ Benign aggregates, by contrast, tend to be smaller, well-circumscribed, centrally located within the marrow space, and composed of a healthy mix of both B and T cells.

When the microscopic picture alone is not enough, additional tests come into play. Immunohistochemistry, which uses antibodies to identify the types of cells present, is a standard next step. A practical diagnostic guideline published in the Journal of Clinical Pathology concluded that combining the aggregate’s location, border characteristics, and immunohistochemical profile provides the most reliable way to distinguish reactive from neoplastic nodules.⁴ In cases where even that panel leaves doubt, molecular clonality testing can detect whether the cells are all descendants of a single ancestor (suggesting lymphoma) or a diverse, polyclonal population (suggesting a benign reaction).⁵

In some inherited immune conditions, the picture gets even murkier. In autoimmune lymphoproliferative syndrome (ALPS), a genetic disorder affecting how immune cells are regulated, bone marrow lymphocytosis and lymphoid aggregates are the predominant finding, showing up in roughly three-quarters of biopsies. These aggregates are often T-cell dominant, which is unusual and can further complicate diagnosis.⁶

Lymphoid Aggregates in the Gut

The gastrointestinal tract is immune-rich territory by design. Your intestinal lining encounters a constant parade of bacteria, food particles, and potential pathogens, so it maintains organized immune tissue, including Peyer’s patches in the small intestine and scattered lymphoid follicles throughout. When those follicles multiply or enlarge beyond their usual baseline, pathologists may describe the finding as nodular lymphoid hyperplasia (NLH). This is generally an asymptomatic condition discovered incidentally during endoscopy, characterized by multiple small nodules usually between 2 and 10 mm scattered along the intestine.⁷

NLH is typically benign and often requires no treatment beyond managing whatever underlying condition drove it, such as an immune deficiency or a chronic infection. It has been linked to common variable immunodeficiency and infections like Giardia and Helicobacter pylori.⁸ When NLH is extensive and involves the colon, its appearance at colonoscopy can be strikingly similar to polyposis syndromes, including familial adenomatous polyposis and multiple lymphomatous polyposis, though it is easily distinguished by biopsy.⁹ The condition is considered a risk factor for intestinal lymphoma, but the actual rate of progression is low.⁷

The story with the stomach is slightly different. Gastric lymphoid follicles are strongly tied to H. pylori infection. One referral-hospital study found lymphoid follicles in 59% of H. pylori-positive patients compared to just 3% of H. pylori-negative patients.¹⁰ These follicles are considered precursors of mucosa-associated lymphoid tissue (MALT), and with prolonged, untreated H. pylori infection, the risk of progressing to gastric MALT lymphoma goes up. Gastric MALT lymphoma is a real entity, but treating the underlying H. pylori infection with antibiotics often leads to complete remission, especially when the lymphoma is caught early and remains localized.¹¹ The practical implication: gastric lymphoid follicles on a biopsy are not cancer, but they are a reason to test for and treat H. pylori if it is present.

Rectal Lymphoid Hyperplasia and Long-Term Follow-Up

Localized lymphoid hyperplasia of the rectum is a specific variant that deserves separate mention because it comes with its own follow-up data. Most cases found incidentally during routine colonoscopy in people without symptoms follow a benign course and resolve on their own. However, a long-term outcomes study found that patients who had persistent symptoms or whose lesions looked nodular or mass-like at endoscopy were at somewhat higher risk of clinically significant disease. The study recommended follow-up endoscopy for those subtypes, and noted that mass-like lesions may warrant continued monitoring even after complete removal.¹² For the average person whose colonoscopy turns up a small, incidental lymphoid aggregate in the rectum, the outlook is reassuring.

The Autoimmune Connection

Autoimmune diseases create exactly the kind of sustained immune stimulation that drives lymphoid aggregate formation, and a few autoimmune conditions carry a well-documented, if still relatively small, risk of those aggregates eventually giving rise to lymphoma. The two most studied examples are Hashimoto’s thyroiditis and Sjögren’s syndrome.

Hashimoto’s thyroiditis causes chronic immune-cell infiltration of the thyroid gland. In rare cases, this chronic stimulation provides a setting in which thyroid MALT lymphoma can develop.¹³ Thyroid MALT lymphoma is uncommon, and the vast majority of people with Hashimoto’s will never develop it, but it is a recognized association that thyroid specialists keep in mind when evaluating unusual nodules in patients with longstanding Hashimoto’s.

Sjögren’s syndrome, an autoimmune disorder that attacks moisture-producing glands, has a stronger and more studied link to salivary gland MALT lymphoma. Research has shown that most of these lymphomas express antibodies selected for binding to a specific part of immunoglobulin G, underscoring the idea that chronic autoimmune stimulation itself is the fuel for the malignant transformation.¹⁴ Clinical red flags for lymphoma in Sjögren’s patients include persistent parotid gland enlargement, enlarged lymph nodes, an enlarged spleen, and certain laboratory changes such as dropping immunoglobulin levels or loss of a previously positive rheumatoid factor.¹⁵ Patients with Sjögren’s are typically monitored for these signs over time, and the overall lifetime risk, while elevated compared to the general population, remains in the single digits for most.

Lymphoid Aggregates in the Lungs

In the airways, lymphoid aggregates take a form called bronchus-associated lymphoid tissue, or BALT. This tissue is not normally present in healthy adult lungs; it forms in response to infections, chronic inflammation, or autoimmune conditions. When lymphoid follicles pack around the small airways, the result can be follicular bronchiolitis, a condition that causes cough and shortness of breath and falls within a broader family of lung diseases collectively called lymphoproliferative disorders of the lung. Despite that intimidating category name, follicular bronchiolitis itself is benign, but it needs to be carefully distinguished from its more serious relatives because treatment and prognosis differ significantly.¹⁶

Animal research has also highlighted a potentially protective role for BALT. In a mouse vaccination model studying tularemia, the formation of BALT after nasal challenge in vaccinated animals appeared to play a role in local immune regulation and long-term protection, though the precise mechanisms are still being worked out.¹⁷ This fits the broader picture: lymphoid aggregates in tissue are not pathology in themselves. They are immune infrastructure, and in many contexts they are protective.

When Lymphoid Structures Inside Tumors Are Actually Good News

One of the more counterintuitive findings in recent cancer research is that lymphoid aggregates forming inside or around solid tumors tend to be a positive prognostic sign, not a negative one. These organized immune clusters, when they develop within the tumor microenvironment, are called tertiary lymphoid structures (TLS). They are essentially the same phenomenon as the aggregates described elsewhere in this article, just occurring at a tumor site rather than in response to infection or autoimmunity.

Across numerous cancer types, the presence of TLS is associated with better outcomes and stronger responses to immunotherapy, with few exceptions.¹⁸ In hepatocellular carcinoma treated with immunotherapy, for instance, a high density of TLS within the tumor at the time of surgery was associated with pathologic response and improved relapse-free survival.¹⁹ The location, composition, and maturity of TLS all matter; not all TLS are equally helpful, and researchers are still working out the details of which structural features predict the strongest immune response.²⁰

The practical upshot is that oncologists are increasingly viewing TLS not as bystander inflammation but as active immune hubs where the body mounts a coordinated anti-tumor response. This has spurred interest in therapies that could deliberately induce or strengthen TLS within tumors, essentially harnessing the body’s own tendency to build lymphoid outposts at sites of trouble.

Bioengineering Lymphoid Tissue on Purpose

If lymphoid aggregates can help the immune system fight tumors, the logical next question is whether you can build them intentionally. Researchers are actively exploring this. Bioengineered artificial lymphoid organs are being investigated as potential tools for treating immune deficiencies, autoimmune diseases, and cancer.²¹ The idea is to create scaffolds, using materials like hydrogels and nanoparticles, that provide the molecular cues needed to trigger the body to form functional lymphoid structures at a chosen location.²²

This work is still early-stage, but it underscores a fundamental point: lymphoid aggregates are not inherently dangerous. They are a normal part of how the immune system adapts, and in many contexts they are beneficial enough that scientists are trying to engineer them from scratch. The cases where lymphoid aggregates become worrisome are specific and identifiable: longstanding H. pylori infection in the stomach, certain autoimmune diseases with chronic glandular inflammation, mass-like lesions in the rectum, and a handful of other well-defined clinical scenarios. Outside those contexts, a pathology report noting lymphoid aggregates is much more likely to reflect a healthy immune system doing exactly what it is designed to do.